Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO
After lining up an application for FDA approval of a new approach to treating fluid retention in heart failure patients a few months ago, Burlington, MA-based scPharmaceuticals is shooting for a $100 million IPO.
The biotech has developed a new formulation of furosemide so it could be delivered via a wearable device, rather than delivered through an IV in the hospital. The combo has the simple intention of reducing the number of days a patient has to be hospitalized for therapy — in a heart failure market that accounts for millions of patients — and the biotech has plans for more IV-replacement programs much like it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.